×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Three patients with papillary renal cell carcinoma (PRCC ) and MET aberrations had partial responses with durations from 39 to 147 weeks.
30952639
2019
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
BEFREE
In metastatic pRCC with a MET amplification, crizotinib maybe a potential met-inhibitory therapeutic option.
30466410
2018
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Both primary tumors and metastases expressed typical markers of pRCC and carried the same activating MET mutation as the parental tumor.
27715452
2017
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
BEFREE
Results Of 109 patients treated, PRCC was MET driven in 44 (40%) and MET independent in 46 (42%); MET status was unknown in 19 (17%).
28644771
2017
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
SomaticCausalMutation
disease
ORPHANET
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
26536169
2016
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
26718059
2016
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Two PRCC PDX models were identified and MET mutation status and copy number determined.
25779944
2015
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Mutations in the MET oncogene are an essential step into the pathogenesis of hereditary pRCC forms, but they can be found only in a small rate of sporadic cases.
26052049
2015
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Finally, germline mutations of the c-Met gene have been proposed as the first predictor of response to targeted therapies in papillary renal cell carcinoma .
24495452
2015
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
CTD_human
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
25401301
2015
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
BEFREE
Overall, this study provides evidence that Chromosome 7 gain drives MET gene copy number increase in PRCC tumors, and appears to subsequently lead to an increase in MET protein overexpression in these tumor cells.
26636767
2015
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
BEFREE
The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors.
24812413
2014
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC ).
23213094
2013
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
CLINGEN
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
18055465
2008
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
BEFREE
The MET oncogene was causally involved in the pathogenesis of a rare tumor, i.e., the papillary renal cell carcinoma , in which activating mutations, either germline or somatic, were identified.
16651428
2006
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Activating mutations affecting the MET receptor tyrosine kinase are present in several types of human cancer, particularly in papillary renal cell carcinoma .
15767811
2005
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
CLINGEN
The MET oncogene drives a genetic programme linking cancer to haemostasis.
15772665
2005
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
CLINGEN
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele.
15557554
2004
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
GeneticVariation
disease
BEFREE
Alterations of known genes in PRCC include missense mutations in the MET oncogene (7q31) and rare translocations fusing TFE3 at Xp11.2 with a variety of other loci.
12213728
2002
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
CLINGEN
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.
10433944
1999
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
CLINGEN
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
9140397
1997
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
CLINGEN
Activating mutations for the met tyrosine kinase receptor in human cancer.
9326629
1997
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
CLINGEN
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors.
1917129
1991
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
Biomarker
disease
HPO
×
Entrez Id:
4233
Gene Symbol:
MET
MET
0.800
CausalMutation
disease
CGI